Blinatumomab for children with steroid-resistant nephrotic syndrome
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a drug called blinatumomab for children with a kidney condition that doesn't respond to standard treatments. It aims to see if it can help when other drugs have failed or caused side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 2 and 17 years
- Has steroid-resistant nephrotic syndrome that didn't improve with calcineurin inhibitors or other immunosuppressants
- Kidney biopsy shows minimal change disease or focal segmental glomerulosclerosis
- No severe kidney damage (eGFR at least 60 mL/min/1.73 m²)
- No active infections like hepatitis B, C, or HIV
- No history of stroke or seizure in the past 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called blinatumomab for children with active lupus that hasn't improved with standard treatments. It aims to see if this immunotherapy can help calm the immune system and reduce lupus activity.
This trial tests whether a drug called rituximab can help children with their first episode of nephrotic syndrome stay in remission longer. It is for children who have already responded to steroid treatment.
This trial tests a new CAR-T cell treatment for children and adults with steroid-resistant nephrotic syndrome (SRNS), a kidney condition that doesn't get better with standard medicines. The goal is to see if this therapy can help improve kidney function when other treatments have failed.
This study tests an injection (SG301) that targets a protein called CD38 to help children whose nephrotic syndrome keeps coming back or depends on steroids. The goal is to see if the treatment can reduce relapses and the need for steroids.
This trial tests a new medicine called zuberitamab for children who have just had their first episode of nephrotic syndrome and have responded well to steroids. The goal is to see if this medicine can help keep the disease from coming back, with fewer side effects than standard treatments.
This trial tests a new drug called telitacicept to help children whose nephrotic syndrome keeps coming back often or who need steroids to stay in remission. The goal is to see if it can keep urine protein levels low and reduce relapses.
Hear when a new CNI-resistant Steriod Resistant Nephrotic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.